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post-transplant laronidase 
augmentation for children with 
Hurler syndrome: biochemical 
outcomes
troy c. Lund1, Weston p. Miller1,6, Ai Yin Liao3, Jakub tolar1, Ryan Shanley2, Marzia pasquali4, 
nicole Sando1, Brian W. Bigger3, Lynda e. polgreen5 & paul J. orchard1
Allogeneic hematopoietic cell transplantation (HCT) benefits children with Hurler syndrome (MPS-IH). 
However, survivors remain burdened by substantial MpS-iH related residual disease. We studied 
the feasibility, safety and biochemical impact of augmentative recombinant intravenous enzyme 
replacement therapy (iV-eRt) post transplantation. ten children with MpS-iH and ≥2 years from 
successful HCT underwent IV-ERT for 2 years’ duration. Patients were monitored for anti-drug 
antibody (ADA) development, including inhibitory capacity and changes in urinary excretion of 
glycosaminoglycans (uGAG). three patients demonstrated low-level ADA at baseline, though all 
children tolerated IV-ERT well. Eight patients developed ADA over the 2-year study, with 3 (38%) 
meeting criteria for an inhibitory ADA response. the aggregate cohort experienced a reduction in uGAG 
from baseline to study end, which was enhanced in children with low or no ADA response. conversely, 
children with inhibitory ADA showed increase in uGAG over time. iV-eRt in previously transplanted 
children with MpS-iH appears safe and can reduce uGAG, although this is reversed by the presence 
of inhibitory ADA. these data show a biochemical change after initiation of post-Hct iV-eRt, but the 
occurrence of ADA and inhibitory antibodies are a concern and should be monitored in future efficacy 
trials. this trial was registered at www.clinicaltrials.gov, NCT01173016, 07/30/2010.
Severe mucopolysaccharidosis type I, or Hurler syndrome (MPS-IH), is a rare, autosomal recessive disorder of 
glycosaminoglycan (GAG) catabolism. Affected patients demonstrate low-to-absent functional α-L-iduronidase 
activity with resulting pathologic accumulation of GAG. If untreated, the disease is characterized by progressive 
and severe organ dysfunction (cardiac, airway/pulmonary, central nervous system [CNS], musculoskeletal) and 
typically results in death within the first decade1. Since the first report of the use of allogeneic hematopoietic 
cell transplantation (HCT) for MPS-IH in 1981, HCT has emerged as the recommended therapy for children 
diagnosed at an early age and yet to experience significant neurodevelopmental decline2. HCT attenuates dis-
ease as donor-derived hematopoietic cells serve as a source of functional α-L-iduronidase for the degradation 
of GAG within recipient somatic and CNS tissue3. Over the past 3 decades, engrafted survival outcomes have 
improved following HCT for children with MPS-IH4,5. However, as these patients live longer, it has become 
evident that transplant does not fully ameliorate the disorder. In a recent, retrospective, multi-center study of 
217 patients with MPS-IH surviving HCT, investigators catalogued high incidences of substantial and morbid 
residual Hurler-related disease. Importantly, they correlated increased disease burden with lower post-transplant 
circulating leukocyte α-L-iduronidase activity, a finding begging the clinical question of whether augmentative 
enzyme sources might be beneficial6.
Laronidase is a recombinant α-L-iduronidase product licensed for intravenous enzyme replacement therapy 
(IV-ERT) in all phenotypes of MPS-I, including Hurler syndrome, the severest disease form. Laronidase is alone 
insufficient to treat the CNS disease associated with MPS-IH as it does not adequately penetrate the blood-brain 
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barrier. However, laronidase IV-ERT has been incorporated into peri-transplant regimens by many centers on 
the basis that it might improve pre-transplant somatic disease and decrease transplant-related complications. 
Initial reports suggest this to be a safe and effective strategy, even as the immunogenic potential of IV-ERT to elicit 
inhibitory anti-drug antibodies (ADA) in this setting is documented7,8. However, for patients with MPS-IH who 
have undergone successful HCT in the distant past, studies of the use of laronidase IV-ERT to augment therapy 
are lacking. We evaluated the safety, immunogenicity and biochemical effect of IV-ERT in patients with MPS-IH 
who were 2 years or greater from HCT with evidence of donor engraftment. Here we describe the incidence and 
impact of ADA, including inhibitory capacity, on donor hematopoietic chimerism and urinary GAG excretion 
(uGAG) over two years’ duration of laronidase treatment.
Results
Ten children with MPS-IH underwent post-transplant IV-ERT augmentation of and completed 2 years of ERT 
on this study. The median age at the initiation of ERT augmentation was 9.5 years (range, 5.1 to 13.8 years). The 
median time from HCT to study entry was 3.7 years (range, 2.4 to 13.1 years). While on study, one patient had a 
seizure thought to be unrelated to IV-ERT treatment. Table 1 shows patient- and disease-related characteristics at 
study entry, as well as the number of doses of drug not administered.
Three patients (ID’s 004, 005, 010) demonstrated low-titer ADA at baseline prior to beginning IV-ERT aug-
mentation with a maximum observed titer of 400 by a commercial assay (Com) and 512 by an independent assay 
(Ind) (Table 1 and Fig. 1A). The remaining 7 patients had no measurable ADA at enrollment. When comparing 
the patients with and without baseline ADA, there were no significant differences in pre-treatment urinary excre-
tion of heparan sulfate (HS), I0S0, or I0S6; however, patients without baseline ADA had slightly higher donor 
hematopoietic chimerism at enrollment (91% versus 86%; p < 0.01). Three patients (ID’s 004, 007, 009) had base-
line leukocyte α-L-iduronidase activity levels below the lower limit of normal (Table 1). Two of these patients 
previously underwent related-donor HCT, and both donors demonstrated normal leukocyte iduronidase activity. 
The third patient was transplanted with unrelated umbilical cord blood unit. All individuals showed predominant 
donor hematopoietic engraftment of at least 75%.
Two patients (ID’s 001 and 002) mounted no anti-laronidase ADA response for the entirety of the study 
(neither apparent at baseline nor at subsequent testing). Of the remaining 8 patients, 3 developed high ADA 
responses (ID’s 006, 007, and 011). Individual patient maximal ADA titers as measured by the independent assay, 
along with concurrent values from the commercial assay, and ADA inhibitory function data are shown in Table 2.
Changes over time in urine HS excretion, as well as ADA titers measured by both assays, are shown for each 
patient in Fig. 1A. When considering the entire cohort, significant decrements in intra-patient uGAG (HS, I0S0, 
and I0S6) were observed between baseline and study’s end (month 24) (Table 3 and Fig. 1B). When considering 
only patients with a low ADA response (n = 7), this effect was enhanced. In contrast, for patients with a high ADA 
response (n = 3), significant intra-patient increase in urinary HS excretion was observed between baseline and 
study’s end. For this same group, urinary excretion of I0S0 and I0S6 appeared higher at month 24 than baseline, 
though the intra-patient difference did not reach statistical significance.
No significant changes in donor hematopoietic chimerism were noted between study enrollment and study’s 
end (month 24) for the entire cohort, and this observation was independent of ADA or inhibitory antibody status 
(Table 4).
Discussion
Based on clinical studies documenting the benefit of full engraftment and higher enzyme levels positively influ-
encing long term outcomes6, and animal data suggesting a dose-response effect of enzyme delivery9, we hypoth-
esized that there may be better biochemical correction with the addition of IV-ERT after transplant. Our study is 
the first to test the biochemical changes that accompany the addition of IV-ERT after allogeneic transplantation 
ID
Prior 
ERT Sex
Age at 
HCT
HCT 
Graft
Age at 
Study
Baseline 
ADA (titer)
IDUA 
activity
Chimerism 
(% donor)
Baseline Urine GAG 
(mg/mmol creatinine)
% Doses 
Missed
HS I0S0 I0S6
001 no F 8 m URD 13y 0 nl 79% 1.30 0.03 0.18 0%
002 yes M 33 m UCB 5y 0 nl 99% 0.67 0.01 0.15 1%
004 yes F 35 m UCB 5y 400 low 77% 1.70 0.07 0.40 0%
005 yes M 16 m UCB 8y 100 nl 81% 0.61 0.01 0.10 11%
006 no F 2 m UCB 10y 0 nl 72% 0.76 0.02 0.10 6%
007 no M 32 m RD 13y 0 low 90% 1.30 0.04 0.23 6%
008 no M 9 m UCB 11y 0 nl 100% 0.61 0.01 0.11 1%
009 yes F 24 m RD 10y 0 low 100% 0.91 0.02 0.14 1%
010 no M 31 m RD 8y 100 nl 100% 0.74 0.02 0.12 0%
011 yes M 7 m RD 9y 0 nl 100% 1.10 0.04 0.18 0%
Table 1. Baseline characteristics at study entry of 10 children with Hurler syndrome receiving post-transplant 
IV-ERT augmentation. F = female; M = male; m = months; URD = unrelated donor; UCB = umbilical 
cord blood; RD = related donor; y = years at study entry; ADA = anti-drug antibody titer by commercial 
assay; IDUA = leukocyte iduronidase activity; nl = within normal limits; low = lower than normal range; 
GAG = glycosaminoglycans; HS = heparan sulfate; I0S0 and I0S6 denote MPS-I-specific non-reducing ends.
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for Hurler syndrome. We show that eight patients mounted anti-laronidase antibody responses while on study; 
only 3 of these patients met high inhibitory ADA response criteria as previously reported10. Intra-patient reduc-
tions in uGAG between baseline and study’s end (month 24) were observed for the aggregate cohort. This effect 
was strengthened among 7 patients in whom no or low-ADA response occurred. Importantly, however, in the 
3 patients with high inhibitory ADA response, the effect was not only negated, but an aggregate increase in 
uGAG (from baseline to month 24) was observed (Fig. 1; Table 3). For the collective cohort, independent of ADA 
response, the donor hematopoietic graft remained stable and appeared unaffected by IV-ERT augmentation.
Urinary GAG excretion is a well-described biomarker in both untreated and treated MPS-IH, and it is known 
that patients demonstrate uGAG reduction, along with clinical benefit, following either IV-ERT or HCT11–14. 
Some data suggest that HCT provides superior uGAG reduction compared to IV-ERT, while other reports have 
shown that HCT adds a step-wise, incremental reduction in uGAG when it follows IV-ERT8,15. However, few 
studies have correlated the magnitude of a clinical benefit with the degree of reduction in uGAG, regardless of the 
therapeutic intervention achieving it.
In an analysis of children undergoing sequential IV-ERT followed by HCT, Saif and colleagues demonstrated 
universal ADA response in the window between ERT initiation and HCT7. When limited to receiving ERT prior 
to transplantation, most children experienced ADA loss by 3 months after HCT, and all were ADA negative by 2 
years following transplant. Most patients’ ADA were determined to be inhibitory, either for enzymatic catalytic 
function or cellular uptake7.
The clinical consequences of ADA in MPS-IH patients, either in the post-transplant or IV-ERT setting, are not 
well-established. Recently, Pal and colleagues compared post-intervention uGAG levels with the presence and 
Figure 1. Individual patient anti-drug antibody response and urine biomarker excretion over time. (A) 
BL (baseline) indicates data acquisition just prior to the first dose of IV laronidase. Numbers on the x-axes 
indicate months on study. Left y-axes show urine heparan sulfate excretion in mg/mmol creatinine (black 
line). Right y-axes (logarithmic scale) show anti-laronidase antibody (ADA) titers, blue dashed line shows the 
titer of commercial (Com) assay, the red solid line shows independently performed titers (Ind). (B) Excretion 
of heparan sulfate, NRE I0S6, and NRE i0S0. Circles indicated geometric mean values; whiskers show 95% 
confidence intervals. Note that the geometric mean is not defined when any value is zero or negative (so is left 
blank). See Table 3 for statistical comparisons of baseline values to those at 24 months. The non-MPS values are 
shown as dashed lines in the graphs. I0S0 non-MPS is not detectable.
4Scientific RepoRtS |         (2019) 9:14105  | https://doi.org/10.1038/s41598-019-50595-1
www.nature.com/scientificreportswww.nature.com/scientificreports/
severity of sleep-disordered breathing among treated MPS-IH patients10. Similar to our findings, they showed 
there were significant differences in uGAG among MPS-IH patients who demonstrated high versus low/no inhib-
itory ADAs. They further showed that high inhibitory antibody response correlated with greater sleep-disordered 
breathing10. Whether the magnitude of uGAG change correlates to other clinical disease manifestations (orthope-
dic, cardiac, neurologic, cognitive, etc.) is not yet clear, and the use of ERT following HCT has not been supported 
nor recommended.
Xue et al. showed there was in inverse relationship between the ADA response and percent reduction in uri-
nary GAG in a meta-analysis of MPS I patients receiving ERT (patients had not undergone HCT)14. Unlike the 
clinical findings of Pal et al., no relationships between the ADA response and changes in percent predicted forced 
vital capacity and six-minute walk test were observed14.
We show the potential for IV-ERT augmentation to significantly reduce uGAG in post-transplant MPS-IH 
patients. Correlation of uGAG response with clinical endpoints for this cohort are important and are reported 
separately16. However, we also show that high inhibitory ADA response in this setting leads to increased uGAG. 
Both ADA and uGAG response beyond termination of IV-ERT at study’s end are not currently known. Despite 
a biochemical change in patients undergoing ERT post-transplant and because of the concern for ADA devel-
opment, uGAG, ADA and inhibitory antibody responses should be monitored. Given the chronic nature of 
bony disease in MPS-IH, a longer-term study on the effect of ERT post-transplant should be performed before 
post-transplant ERT can be firmly recommended.
Methods
participants. Patients with a diagnosis of Hurler syndrome and ≥ 2 years out from HCT were eligible for this 
study. This study was approved by the Committee on the Use of Human Subjects in Research at the University 
of Minnesota, and all experiments were performed in accordance with relevant guidelines and regulations by 
Condition n Baseline GM (95% CI) Month 24 GM (95% CI) GM Ratio (95% CI)
p-value 
(ratio)
Heparan sulfate (mg/mmol creatinine)
All 10 0.91 (0.74, 1.12) 0.66 (0.57, 0.76) 0.72 (0.58, 0.90) <0.01
Low/No ADA 7 0.87 (0.66, 1.14) 0.45 (0.38, 0.54) 0.52 (0.39, 0.69) <0.01
High ADA 3 1.03 (0.80, 1.33) 1.57 (1.27, 1.95) 1.53 (1.06, 2.21) 0.02
I0S6 (mg/mmol creatinine)
All 10 0.16 (0.12, 0.20) 0.07 (0.06, 0.09) 0.48 (0.38, 0.60) <0.01
Low/No ADA 7 0.15 (0.11, 0.21) 0.05 (0.04, 0.06) 0.29 (0.24, 0.37) <0.01
High ADA 3 0.16 (0.11, 0.24) 0.24 (0.17, 0.32) 1.46 (0.83, 2.58) 0.19
I0S0 (mg/mmol creatinine)
All 10 0.022 (0.015, 0.032) 0.014 (0.010, 0.020) 0.627 (0.408, 0.963) 0.03
Low/No ADA 7 0.019 (0.011, 0.031) 0.008 (0.005, 0.013) 0.431 (0.245, 0.759) <0.01
High ADA 3 0.032 (0.022, 0.046) 0.048 (0.028, 0.081) 1.500 (0.859, 2.619) 0.15
Table 3. Urinary excretion of glycosaminoglycan biomarkers at baseline and after 2 years of IV-ERT 
augmentation using a generalized estimated equations model to assess intra-patient changes. GM = geometric 
means from the generalized estimated equations model; GM ratio = ratio of geometric means at 24 months 
compared to baseline; CI = confidence interval; ADA = anti-drug drug antibody; p-values are from tests of the 
null hypothesis that the true GM ratio (month 24/baseline) is 1.
ID
Maximum Anti-drug Antibody@ Month 24 Anti-drug Antibody
ADA 
Classification
Titer 
(Com)
Titer 
(Ind) % Inhibition
Titer 
(Com)
Titer 
(Ind) % Inhibition
001 0 0 — 0 0 — Low/No
002 0 0 — 0 0 — Low/No
004 1,600 512 — 0 64 — Low/No
005 800 32,768 18% 100 256 0% Low/No
006 51,200 65,536 56% 25,600 16,384 94% High
007 102,400 524,288 87% 51,200 65,536 98% High
008 0 8,192 10% 0 0 9% Low/No
009 1,600 1,024 0% 0 0 0% Low/No
010 12,800 4,096 46% 400 256 0% Low/No
011 3,200 262144 40% 3,200 4,096 23% High
Table 2. Determination of high ADA responders versus low/no ADA responders for 10 children with Hurler 
syndrome receiving post-transplant laronidase IV ERT augmentation. @Each patient’s maximum antibody 
titer time-point as determined by the independent assay (Ind); the concurrent titer from the commercial assay 
(Com) is shown for comparison; ADA = anti-drug antibody.
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the Committees on the Use of Human Subjects in Research at the University of Minnesota. The methods were 
carried out in accordance with the relevant guidelines and regulations. Informed consent was obtained from all 
participants and/or their legal guardian/s. This study was registered on clinicaltrials.gov (NCT 01173016, July 
30th, 2010). Eleven patients were enrolled. One patient dropped out at 6 months due to the time involved in ERT 
infusions and uncertainty about continuation in the study (their data is not included in our analyses). Ten par-
ticipants completed the study. Following informed consent, patients underwent a baseline evaluation, and began 
IV-ERT (laronidase, 0.58 mg/kg IV weekly) for 104 consecutive weeks. Infusion-related toxicities were recorded. 
Demographic, transplant-related, and biochemical data including leukocyte α-L-iduronidase activity as meas-
ured by a clinical laboratory assay were recorded at baseline.
chimerism. Chimerism was assessed on the myeloid fraction (with ≥98% purity) of peripheral blood by our 
clinical laboratory after positive immune-magnetic selection of the CD15+ cell population. In cases where pos-
itive selection did not occur, whole blood samples were analyzed (ID 006). Donor chimerism was performed by 
polymerase chain reaction amplification of donor-specific short tandem nucleotide repeats.
Anti-drug antibody. Patients underwent longitudinal evaluations of donor hematopoietic chimer-
ism, laronidase ADA titers, and uGAG at baseline (prior to first laronidase dose) and every 3 months (ADA 
titers and uGAG) or every 6 months (chimerism) throughout the 2-year treatment duration. ADA titers were 
assessed in parallel by two methods. In the first, plasma samples were submitted to the drug manufacturer for 
the commercially-available (Com) determination of total ADA titer using end-point titration14. For the second 
method, we independently (Ind) evaluated concurrent plasma samples for ADA titer as previously described10. 
Furthermore, for all patients who mounted an ADA titer ≥1,000 at any time-point on study as measured by the 
independent assay, we determined ADA inhibitory capacity at two time-points: at ADA titer peak and at the 
end-of-study (month 24). As previously described, this inhibitory assay registered ADA’s sum total interference 
with both enzyme cellular uptake and catalytic function10. Patients were considered to have high ADA response 
if their maximum titer on study was ≥4,000 (using either ADA method) and the mean inhibition (averaged 
between the inhibition at the ADA titer peak and at month 24) was ≥30%, as previously described10. All other 
patients were considered to demonstrate low/non-significant ADA responses. Quantitative urinary GAG excre-
tion was performed using the Sensi-Pro assay to measure non-reducing ends (NREs) characteristic for MPS-IH: 
I0S0, I0S6, and total HS concentration17,18.
Statistical analysis. Patients with measurable laronidase ADA at study entry (n = 3) were compared to 
those without baseline ADA (n = 7) for the following pre-IV-ERT parameters: donor hematopoietic chimerism 
level and urinary excretion of HS, and the non-reducing ends I0S0, and I0S6. Differences in the mean values 
between the two groups were assessed with t-tests. Changes in donor hematopoietic chimerism and uGAG over 
time (HS, I0S0, and I0S6) were analyzed using a generalized estimating equations model (GEE), accounting for 
correlation among repeated measurements from the same subject. Outcome variables were log-transformed to 
stabilize residual variance, thus geometric means (GM) were calculated. Estimations of the change in uGAG at 
study’s end (month 24) compared to entry (baseline) were expressed as GM ratios (null hypothesis that the true 
GM ratio = 1, or that no change in uGAG would occur). Changes in donor hematopoietic chimerism between 
baseline and 24 months were analyzed in a similar manner19. Analyses were performed using SAS version 9.3 
(SAS Institute, Cary, NC, USA).
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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